Search Results
Your search for it matches 15474 pages
Showing 10301 - 10350City of Hope Awarded NCI Research Grant for Potential Acute Myeloid Leukemia Drug
A City of Hope research team led by Steven T. Rosen, MD, City of Hope’s Provost and Chief Scientific Officer, has been awarded a $2.3 million Research Project Grant (R01) from the National Cancer Institute (NCI) to fund studies associated with a phase I/II clinical trial in relapsed/refractory...
Neoadjuvant Endocrine Therapy Vastly Underutilized by U.S. Clinicians
Neoadjuvant endocrine therapy in the management of breast cancer is woefully underutilized by U.S. clinicians, according to advocates of this approach who made their case at the 2016 Miami Breast Cancer Conference.1 In postmenopausal women with estrogen receptor–rich tumors, neoadjuvant endocrine...
In Ductal Carcinoma in Situ, Benefit of Wider Margins Tied to Radiation Use
The relationship between margin width and risk of recurrence after breast-conserving surgery for ductal carcinoma in situ depends on the use of radiation, according to a surgical oncologist who sought to determine the optimal margin width in these patients.1 “Positive margins are associated with an ...
Expert Point of View: Kian Behbakht, MD
Kian Behbakht, MD, Professor of Gynecologic Oncology at the University of Colorado School of Medicine, Aurora, said that the study underscored the surgical importance of getting to no visible residual disease in ovarian cancer. “Based on today’s data,” said Dr. Behbakht, “it seems as though it’s...
AACR 2016: Delays in Radiation Therapy Increase Chance of Breast Tumor Development in Women Treated for DCIS
Women who underwent treatment for ductal carcinoma in situ (DCIS) were at higher risk of developing malignant breast tumors if they did not receive timely radiation therapy as part of their treatment, according to a study presented by Liu et al at the 2016 AACR Annual Meeting (Abstract 2576). DCIS ...
AACR 2016: Comparison of Three Different PD-L1 NSCLC Diagnostic Tests Shows a High Degree of Concordance
Three commercially available diagnostic tests were similarly effective in measuring programmed death ligand 1 (PD-L1) protein expression on non–small cell lung cancer (NSCLC) tumor samples, indicating that health-care providers may someday be able to use these tests interchangeably when...
AACR 2016: Certain Oral Bacteria May Be Associated With Increased Pancreatic Cancer Risk
The presence of two species of bacteria linked to periodontal disease in the mouths of healthy individuals was associated with an increased risk of subsequently developing pancreatic cancer, according to research presented by Fan et al at the 2016 AACR Annual Meeting (Abstract 4350). ...
Study Supports Initial Attempt at Debulking Surgery in Stage IIIC Ovarian, Fallopian Tube, and Peritoneal Carcinoma
In a study exploring the effect of primary debulking surgery in women with bulky stage IIIC ovarian, fallopian tube, and primary peritoneal cancers, cytoreduction to no gross residual disease was associated with the best survival outcomes.1 Cytoreduction to 1 to 10 mm of residual disease was also...
Physicians as Champions for Quality Improvement
Interest in quality measurement and improvement was once primarily a concern of regulators, insurers, and consumer advocates. Today, quality improvement is front and center in health care—a continuous mission requiring the efforts of everyone on the health-care team. At the recent ASCO Quality Care ...
Benefits and Risks of Transplantation: The Changing Therapeutic Paradigm for Multiple Myeloma
Although high-dose chemotherapy plus autologous transplantation has been a standard of care in the treatment of younger patients with newly diagnosed multiple myeloma, the advent of effective novel agents for the cancer over the past 15 years has raised the question of whether transplantation, with ...
Novel Strategies Emerging for Triple-Negative Breast Cancer
Compelling hypotheses are emerging about the mechanisms driving triple-negative breast cancer, and they are driving drug development in this area, according to Joyce O’Shaughnessy, MD, Celebrating Women Chair of Breast Cancer Research at Baylor Charles A. Sammons Cancer Center. She is also Medical...
AACR 2016: Palbociclib Shows Antiproliferative Activity in Early-Stage Breast Cancer
The molecularly targeted therapeutic palbociclib (Ibrance) was effective in slowing the multiplication of cancer cells in patients diagnosed with early-stage breast cancer who received no prior therapy, according to data from a phase II clinical trial presented by Arnedos et al at the 2016 AACR...
AACR 2016: 5-Year Survival Rates for Patients With Metastatic Melanoma Treated With Nivolumab Much Higher Than Historical Rates
More than a third of metastatic melanoma patients (34%) who received the anti–programmed cell death protein 1 (PD-1) immunotherapeutic nivolumab (Opdivo) in a phase I clinical trial are still alive 5 years after starting treatment, according to research presented by Hodi et al at the 2016...
AACR 2016: LOXO-101 Shows Continued Promise in Patients Whose Tumors Had NTRK Gene Fusions
The investigational drug LOXO-101, which selectively targets a family of proteins called neurotrophic tyrosine kinase receptors (NTRKs), produced significant tumor regression in patients whose tumors had NTRK gene fusions, according to data from a phase I clinical trial presented by Hong et al at...
AACR 2016: RAF-Targeted Therapeutic BGB-283 Shows Early Promise Against Tumors With BRAF and RAS Mutations
The new investigational anticancer therapeutic BGB-283, which targets the RAF family of proteins, was safe, tolerable, and showed signs of clinical activity in patients who had a range of types of cancer with mutations in BRAF, KRAS, and NRAS, according to results from a phase I clinical trial...
ELCC 2016: Studies Confirm Benefit of Plasma Genotyping to Predict Treatment Benefit in Patients With Non–Small Cell Lung Cancer
The benefit of plasma genotyping to predict treatment benefit in patients with non–small cell lung cancer (NSCLC) was confirmed in three studies presented April 15 at the European Lung Cancer Conference (ELCC) 2016 in Geneva. However, researchers warned that plasma tests are unlikely to fully ...
ELCC 2016: Patients With EGFR-Expressing Non–Small Cell Lung Cancer Benefit Most From Necitumumab Added to Chemotherapy
Patients with epidermal growth factor receptor (EGFR)-expressing advanced squamous non–small cell lung cancer benefit most from necitumumab (Portrazza) added to gemcitabine and cisplatin chemotherapy, according to a subgroup analysis from the SQUIRE trial presented by Paz-Ares et al (Abstract ...
ASBS 2016: Fertility Counseling in Women of Childbearing Age After Breast Cancer
Despite recent advances in assisted reproductive technology for women with breast cancer, documented fertility counseling at diagnosis remains low, while 89% of those made aware of their options sought specialized consultation for reproductive preservation. Almost 50% of these women chose one of...
Hypofractionated Radiotherapy Not Inferior to Conventional Radiotherapy in Low-Risk Prostate Cancer
Hypofractionated radiotherapy was not inferior to conventional radiotherapy in terms of disease-free survival among men with low-risk prostate cancer, according to the results of the phase III NRG Oncology RTOG 0415 trial reported in the Journal of Clinical Oncology by Lee et al. However, it was...
Cancer and Fertility Program Improves Patient Satisfaction With Information on Fertility Risks and Preservation
A cancer and fertility program established at Memorial Sloan Kettering Cancer Center (MSKCC) improves patient satisfaction with information received regarding fertility risks and preservation options, according to a report by Kelvin et al in the Journal of Clinical Oncology. Designed to support...
ELCC 2016: Osimertinib Given as First-Line Treatment May Alter Biology of EGFR-Mutated Non–Small Cell Lung Cancer
The third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor osimertinib (Tagrisso) is effective in the first-line treatment of EGFR-mutated non–small cell lung cancer (NSCLC), according to a late-breaking abstract presented by Ramalingam et al (Abstract...
ELCC 2016: Immunotherapy With Live Bacterium Improves Response Rate in Malignant Pleural Mesothelioma
Immunotherapy with a live bacterium combined with chemotherapy demonstrated more than 90% disease control and a 59% response rate in patients with malignant pleural mesothelioma, according to the results of a phase Ib trial presented by Jahan et al April 14 (Abstract 208O_PR) at the European Lung...
The Parker Foundation Launches the Parker Institute for Cancer Immunotherapy With a $250 Million Grant
On April 13, The Parker Foundation announced a $250 million grant to launch the Parker Institute for Cancer Immunotherapy, a collaboration between scientists, clinicians, and industry partners to lead an unprecedented cancer immunotherapy research effort. The gift is the largest single contribution ...
Differences in Marital Status and Cancer Mortality by Race/Ethnicity and Nativity Explored
Previous studies have shown that married patients with cancer fare better than unmarried patients with cancer, surviving more often and longer. In a new study, published by Martínez et al in Cancer, researchers at University of California, San Diego, School of Medicine reported that the...
Preclinical Studies Show Many Androgen-Deprivation Therapies May Suppress Adaptive Immune Responses
Prostate cancer patients and their doctors may want to think twice about the best timing for chemotherapy or radiation therapy in conjunction with a common nonsurgical treatment, based on international research findings led by UT Southwestern Medical Center investigators. Researchers using mouse...
ASCO Urges Aggressive Efforts to Increase HPV Vaccination and Prevent Cancer
Use of human papillomavirus (HPV) vaccines should be rapidly expanded to protect thousands of young people in the United States—and millions worldwide—from life-threatening cancers, ASCO said April 11 in a policy statement. Published by Bailey et al in the Journal of Clinical Oncology,...
Hormone Combination Therapy May Increase Risk of Breast Cancer in African American Women
The use of combination therapy with estrogen plus progestin, previously shown to be associated with an increased incidence of estrogen receptor–positive breast cancer in postmenopausal women in studies based largely on white women, has been shown to increase this type of breast cancer...
Shorter Delays Between Diagnosis, Surgery, and Chemotherapy Initiation May Improve Survival in Breast Cancer
The survival benefits of reducing the time to surgery following a diagnosis of breast cancer, and time to initiation of adjuvant chemotherapy following surgery were outlined in two articles and an accompanying editorial in JAMA Oncology. Analyzing two independent population-based studies with a...
Relatives of Patients With Carcinoma of Unknown Primary at Increased Risk for This and Other Cancers
Relatives of patients with carcinoma of unknown primary are at increased risk of developing it themselves as well as several other malignant neoplasms, including lung, pancreatic, and colon cancers; non-Hodgkin lymphoma; and myeloma, according to a study published in JAMA Oncology. “Some of...
In Early Brain Radiation Recovery Studies, Cranial Grafting of Stem Cell–Derived Therapy Improves Cognition and Reduces Neuropathology
While stem cells have shown promise for treating brain regions damaged by cancer radiation treatments, University of California, Irvine (UCI) researchers have found that microscopic vesicles isolated from these cells provide similar benefits without some of the risks associated with stem cells....
p53- and Mevalonate Pathway–Driven Cancers Require Cell-Signaling Protein Arf6 for Metastasis and Drug Resistance
A metabolic pathway that is upregulated in certain breast cancers promotes the disease's progression by activating a cell-signaling protein called Arf6, according to findings published by Hashimoto et al in the Journal of Cell Biology. The study, conducted by a team of researchers at Hokkaido...
Some Diagnostic Variability in Interpreting Breast Biopsy Slides
Pathologists would disagree about 8% of the time when interpreting a single breast biopsy slide, with more overinterpretation than underinterpretation in discordant cases, according to an analysis combining results from the B-Path (Breast Pathology) study with data on the prevalence of breast...
UK Trial Shows Similar Survival With PET-CT Surveillance vs Planned Neck Dissection in Advanced Head and Neck Cancer
In a UK noninferiority trial reported in The New England Journal of Medicine, Mehanna et al found that positron-emission tomography–computed tomography (PET-CT) surveillance was associated with similar survival vs planned neck dissection in patients with stage N2 or N3 squamous cell carcinoma ...
sFRP2 in Aged Melanoma Tumor Cells Drives Metastasis and Therapy Resistance
Cancer risk increases with one's age as accumulated damage to our cells and chronic inflammation occur over time. Now, an international team of scientists led by The Wistar Institute has shown that aged tumor cells in melanoma behave differently from younger tumor cells, according to study results...
Compartmentalizing Cancer
I was the last one on the oncology team to meet Mel. He was 36 years old, and by then Mel had been living with metastatic colon cancer for several years. During that time, his clinicians had never referred him to our psycho-oncology team because of his strong attitude and outlook. Mel’s outward...
Geriatric Assessment Is Key to Treatment Decisions for Patients 80 Years and Older
A review of major studies and the current literature underscored the role of geriatric assessment in making treatment recommendations for patients aged 80 years and older with early and metastatic breast cancer. The review was published in the Journal of Oncology Practice. The corresponding author...
10 Bladder Cancer Projects Awarded Research Grants by Johns Hopkins Greenberg Bladder Cancer Institute
The Johns Hopkins Greenberg Bladder Cancer Institute is a collaborative initiative of the Johns Hopkins Kimmel Cancer Center, the Brady Urological Institute, the Bloomberg School of Public Health, and the School of Medicine. It aims to develop new clinical strategies for combating bladder cancer...
AACR CEO Margaret Foti, PhD, MD (hc), Honored With James Ewing Layperson’s Award From SSO
Margaret Foti, PhD, MD (hc), CEO of the American Association for Cancer Research (AACR), was recognized during the plenary session at the 69th Society of Surgical Oncology (SSO) Annual Cancer Symposium with the James Ewing Layperson’s Award for her dedication to the prevention and cure of cancer;...
A Political Activist Challenges the Drug Approval Process and the U.S. Government
The U.S. Food and Drug Administration’s (FDA’s) primary concern in the drug approval process is to ensure that the drug is safe and effective. For the past several decades, the advocacy groups have vociferously painted the agency as a stodgy bureaucracy that prevents desperate patients access to...
Things May Not Be What They Seem: Are Old Cancer Treatment Theories New Again?
The adage “you can’t judge a book by its cover,” is true, but authors still need to be aware of the importance of first impressions. The title of science writer Travis Christofferson’s book Tripping Over the Truth: The Return of the Metabolic Theory of Cancer Illuminates a New and Hopeful Path to ...
Crizotinib in ROS1-Positive Metastatic Non–Small Cell Lung Cancer
On March 11, 2016, crizotinib (Xalkori) was approved for treatment of patients with metastatic non–small cell lung cancer (NSCLC) with ROS1 rearrangement–positive tumors.1,2 A U.S. Food and Drug Administration–approved test for the detection of ROS1 rearrangements in NSCLC is not currently...
Lili Yang, PhD, Receives CIRM Funding to Investigate iNKT Modification and Transplantation
With new funding awarded by the California Institute for Regenerative Medicine (CIRM), Lili Yang, PhD, Assistant Professor in the Department of Microbiology, Immunology & Molecular Genetics and the Eli & Edythe Broad Center of Regenerative Medicine and Stem Cell Research (BSCRC) at the...
Cancer on the Global Stage: Incidence and Cancer-Related Mortality in Israel
The ASCO Post is pleased to continue this special feature on the worldwide cancer burden. In this issue, we feature a close look at the cancer incidence and mortality rates in Israel. The aim of this special feature is to highlight the global cancer burden for various countries of the world. For...
Phase Ib/II Study Reports High Response Rates Seen With Addition of Cisplatin to Regimen for Advanced Pancreatic Cancer
The oncology research team at HonorHealth Research Institute in Scottsdale, Arizona, is spearheading a phase Ib/II trial that is demonstrating promising results with a novel regimen in patients with advanced pancreatic cancer. “The patients we are treating have advanced adenocarcinoma of the...
Susan Block, MD, Honored With AAHPM Palliative Care Lifetime Achievement Award
Susan Block, MD, an institute physician in the Department of Psychosocial Oncology and Palliative Care at Dana-Farber Cancer Institute, a Harvard Medical School Professor, and Director of the Serious Illness Care Program at Ariadne Labs, received the Lifetime Achievement Award at the American...
Samuel Waxman Cancer Research Foundation Appoints Robert Hromas, MD, to Its Scientific Advisory Board
The Samuel Waxman Cancer Research Foundation (SWCRF) announced the addition of cancer researcher Robert Hromas, MD, Chair of Medicine at University of Florida Health, to its scientific advisory board (SAB). Dr. Hromas, who continues his position at the University of Florida Health, will join his...
Providing Perspective on Pressing Economic Issues Facing Cancer Care—Now and in the Future
CANCERSCAPE, the 2016 Annual Meeting of the Association of Community Cancer Centers (ACCC), provided a forum for about 300 attendees to gain insight into the complexities of oncology treatment, where “clinical advances, policy mandates, and value-based payment reform intersect.” Of particular...
ASCO Pledges to Advance Interoperability Among Health Information Systems
ASCO has joined members of the health-care community in pledging to the U.S. Department of Health and Human Services (HHS) to commit to principles that will advance interoperability among health information systems. A formal announcement of the initiative was delivered by HHS Secretary Sylvia M....
Understanding and Preparing for MACRA
The Medicare Access and CHIP Reauthorization Act of 2015 (MACRA) was passed in April 2015, introducing comprehensive changes to how Medicare pays physicians for services. As the policies passed in MACRA are rolled out over the coming years, they will profoundly impact reimbursement and care...
Diversity Training Key to Increasing Cultural Competence Among Oncology Surgeons
A study in the Journal of Oncology Practice (JOP)1 measured the level of cultural competence among surgeons from six hospitals in the Puget Sound region of Washington State, home to a large population of American Indians and Alaskan Natives. According to the study, “Assessing Cultural Competence...
